Evidence map›Paper›PMID 30863383›Full record

ArticleFrontiers in microbiology2019

The Antimicrobials Anacardic Acid and Curcumin Are Not-Competitive Inhibitors of Gram-Positive Bacterial Pathogenic Glyceraldehyde-3-Phosphate Dehydrogenase by a Mechanism Unrelated to Human C5a Anaphylatoxin Binding.

Sara Gómez, Javier Querol-García, Gara Sánchez-Barrón, Marta Subias, Àlex González-Alsina, Virginia Franco-Hidalgo, Sebastián Albertí, Santiago Rodríguez de Córdoba, Francisco J Fernández, M Cristina Vega

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Protein-Protein Binding Kinetics by Biolayer Interferometry.Advances in experimental medicine and biology · 2024
    Article
  4. Structural biology of complement receptors.Frontiers in immunology · 2023
    Review
  5. The structure ofFrontiers in immunology · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sara GómezCenter for Biological Research, Spanish National Research Council, Madrid, Spain.
Javier Querol-GarcíaCenter for Biological Research, Spanish National Research Council, Madrid, Spain.
Gara Sánchez-BarrónCenter for Biological Research, Spanish National Research Council, Madrid, Spain.
Marta SubiasCenter for Biological Research, Spanish National Research Council, Madrid, Spain.
Àlex González-AlsinaInstitut Universitari d'Investigació en Ciències de la Salut, University of the Balearic Islands, Mallorca, Spain.
Virginia Franco-HidalgoCenter for Biological Research, Spanish National Research Council, Madrid, Spain.
Sebastián AlbertíInstitut Universitari d'Investigació en Ciències de la Salut, University of the Balearic Islands, Mallorca, Spain.
Santiago Rodríguez de CórdobaCenter for Biological Research, Spanish National Research Council, Madrid, Spain.
Francisco J FernándezCenter for Biological Research, Spanish National Research Council, Madrid, Spain.
M Cristina VegaCenter for Biological Research, Spanish National Research Council, Madrid, Spain.
Instituto de Investigación de Enfermedades Raras · ESServei de Salut de les Illes Balears · ESUniversitat de les Illes Balears · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ubiquitous and highly abundant glycolytic enzyme D-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pivotal for the energy and carbon metabolism of most organisms, including human pathogenic bacteria. For bacteria that depend mostly on glycolysis for survival, GAPDH is an attractive target for inhibitor discovery. The availability of high-resolution structures of GAPDH from various pathogenic bacteria is central to the discovery of new antibacterial compounds. We have determined the X-ray crystal structures of two new GAPDH enzymes from Gram-positive bacterial pathogens,

Indexed as

anacardic acidClostridium perfringenscomplement – immunological termcurcuminenzyme inhibitionGAPDH – glyceraldehyde-3-phosphate dehydrogenaseStreptococcus pyogenesX-ray crystallography

Identifiers

PMID30863383
PMCPMC6400076
OpenAlexW2916511402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.